Connect with us

Technology

Asia-Pacific Single-Cell Multi Omics Market to Surge, Forecasts $1.85 Billion Valuation by 2033, Driven by Expansion into New Research Applications, Such as Single-Cell Metabolomics

Published

on

DUBLIN, March 4, 2024 /PRNewswire/ — The “Asia-Pacific Single-Cell Multi Omics Market: Analysis and Forecast, 2023-2033” report has been added to ResearchAndMarkets.com’s offering.

The Asia-Pacific single-cell multi-omics market is projected to reach $1.85 billion by 2033 from $0.30 billion in 2023, growing at a CAGR of 20% during the forecast period 2023-2033. This robust growth is fuelled by key industry drivers such as advancements in single-cell RNA sequencing, personalized medicine, and a surge in its application within drug development.

The study segments and explores the market dynamics across major APAC countries, including China, Japan, India, Australia, and Singapore. Detailed insights into the competitive landscape reveal strategic growth and marketing strategies adopted by industry stalwarts and emerging players alike. These strategies encompass a spectrum of new product offerings, partnerships, and collaborative efforts designed to propel the market forward.

Market Dynamics

The escalation in precision medicine and disease-specific diagnostics is significantly contributing to the Asia-Pacific single-cell multi omics market growth. With a spotlight on the region’s healthcare infrastructure and government support for genomic research, the market is set to create a nexus for innovation and patient-centric care. Professionals operating in the fields of oncology, immunology, and neuroscience are particularly situated to leverage these advancements and improve therapeutic outcomes.

Technological Integration and Competitive Strategies

With the surge in single-cell multi omics technology, the market is experiencing a wave of strategic alliances. These collaborations span across academia and industry boundaries, focusing on groundbreaking research and development initiatives. Advances in the technology are anticipated to unlock potential applications beyond existing domains, potentially revolutionizing areas such as developmental biology and stem cell research.

The availability of this comprehensive analysis underscores the vital role of single-cell multi omics in shaping the future of healthcare and pharmaceutical research in the Asia-Pacific region. The optimized findings cater to stakeholders seeking to prime their strategic positions within this burgeoning market. The report’s insights are instrumental for research institutions, healthcare providers, and pharmaceutical entities aiming to harness the growth potential and drive inclusive innovation in personalized medicine and genomics research.

Key Topics Covered:

1 Market
1.1 Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.2 Market Overview
1.2.1 Key Findings
1.2.2 Current Market Scenario
1.2.2.1 For Researchers
1.2.2.2 For Diagnostics
1.3 Industry Outlook
1.3.1 Regulatory Framework
1.3.2 Patent Analysis
1.3.2.1 Awaited Technological Developments
1.3.2.2 Patent Filing Trend (by Country)
1.3.2.3 Patent Filing Trend (by Year)
1.3.3 Key Trends
1.3.3.1 Advancements in Imaging Techniques for Single-Cell Sequencing
1.3.3.2 Use of Artificial Intelligence (AI) and Machine Learning (ML) in Single-Cell Multi-Omics
1.3.3.3 Increased Development of Advanced Solution Based on Single-Cell Technology
1.3.4 Opportunity Assessment
1.3.5 Product Benchmarking
1.3.6 Clinical Trials
1.4 COVID-19 Impact
1.4.1 Pre-COVID-19
1.4.2 During COVID-19
1.4.3 Post COVID-19
1.5 Business Dynamics
1.5.1 Impact Analysis
1.5.2 Business Drivers
1.5.2.1 Rising Number of Large-Scale Genomics Studies Leveraging Single-Cell RNA Sequencing (Sc-RNA)
1.5.2.2 Use of Single-Cell Multi-Omics Approach for Screening and Diagnostics of Diseases Leading to Shift Toward Personalized Medicine
1.5.2.3 Increasing Use of Single-Cell Multi-Omics for Drug Development
1.5.2.4 Collaborations among Technology Providers and Life Sciences Companies for Accelerating the Research in Single-Cell Multi-Omics
1.5.3 Business Restraints
1.5.3.1 High Cost of Single-Cell Analysis and Sequencing
1.5.3.2 Limited Availability of Large Online Data Storage and Analysis Platforms
1.5.4 Business Opportunities
1.5.4.1 Expansion into New Research Applications, Such as Single-Cell Metabolomics
1.5.4.2 Increasing Adoption of Genomic-Based Medicine in Emerging Nations

2 Single-Cell Multi-Omics Market (by Region)
2.1 Asia-Pacific
2.1.1 Key Findings and Opportunity Assessment
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Sizing and Forecast Analysis
2.1.3.1 Asia-Pacific Single-Cell Multi-Omics Market (by Country)
2.1.3.1.1 China
2.1.3.1.2 Japan
2.1.3.1.3 India
2.1.3.1.4 Singapore
2.1.3.1.5 Australia
2.1.3.1.6 Rest-of-Asia-Pacific

3 Markets – Competitive Benchmarking & Company Profiles
3.1 Competitive Benchmarking
3.1.1 Key Strategies and Developments
3.1.1.1 Funding Activities
3.1.1.2 New Offerings
3.1.1.3 Mergers and Acquisitions
3.1.1.4 Partnership, Collaboration, and Business Expansion
3.1.2 Market Share Analysis
3.1.3 Growth Share Analysis
3.1.3.1 By Application
3.1.3.2 By Omics Type
3.1.3.3 By Product Type
3.1.4 Visual Graphics of the Companies
3.1.5 Multi-Omics Ecosystem Active Players
3.2 Company Profiles
3.2.1 BGI Group
3.2.1.1 Company Overview
3.2.1.2 Role of BGI Group in the Single-Cell Multi-Omics Market
3.2.1.3 Financials
3.2.1.4 Analyst Perspective
3.2.2 Shilps Sciences
3.2.3 Takara Bio Inc.

For more information about this report visit https://www.researchandmarkets.com/r/u9eahr

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/asia-pacific-single-cell-multi-omics-market-to-surge-forecasts-1-85-billion-valuation-by-2033–driven-by-expansion-into-new-research-applications-such-as-single-cell-metabolomics-302078461.html

SOURCE Research and Markets

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Greater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration

Published

on

By

In the preliminary findings of a study conducted with the National Taiwan University Hospital, over 50% of sample cases were reclassified as HER2-expressing when 3D pathology was applied.

HSINCHU, April 17, 2025 /PRNewswire/ — JelloX Biotech Inc., a Taiwan-based startup at the forefront of cancer pathology, announced the preliminary results of a research collaboration with the National Taiwan University Hospital (NTUH) on breast cancer patients. The study found that JelloX’s 3D pathology technology identified a significantly increased proportion of tumors with HER2-low and HER2-ultralow expression compared to conventional methods, demonstrating this technology’s increased sensitivity and potential as a superior diagnostic tool for HER2 detection in breast cancers.

Contact JelloX at sales@jellox.com to explore partnerships and learn more about the company’s cutting-edge 3D pathology technology.

According to the US National Cancer Institute, breast cancer is the most prevalent form of cancer. However, the difficulty of precisely determining treatment has made the identification of HER2 expression essential. In HER2-low and HER2-ultralow metastatic breast cancer, the novel antibody-drug conjugate (ADC) Trastuzumab deruxtecan (T-DXd) has demonstrated robust efficacy over conventional chemotherapy. Yet considering HER2 spatial heterogeneity, traditional diagnostic methods have shown to be less precise than 3D pathology in detecting the presence of the HER2 protein.

“For the specific challenges posed by metastatic breast cancer and the need to identify predictive biomarkers accurately, the high sampling capacity of 3D pathology holds particular potential,” commented Dr. Yen-Yin Lin, CEO of JelloX. “JelloX Biotech’s Comprehensive HER2 Diagnostic Solution is poised to revolutionize HER2 diagnostics. With a more comprehensive data set on tumor samples, healthcare providers can be empowered to make more precise diagnoses, ensuring that the right patients receive the right treatment at the right time.”

New findings with NTUH on HER2 breast cancer

In JelloX’s research collaboration with NTUH, preliminary findings indicate that more than half of the analyzed cases exhibited diagnostic discrepancies when re-evaluated using the company’s advanced 3D pathology methods. Notably, among patients initially classified as HER2-null by traditional methods, more than 66.7% were reclassified as HER2-expressing (HER2-low or HER2-ultralow) using 3D technology, thereby becoming potentially eligible for T-DXd treatment.

These findings echo the company’s recent results using samples from colorectal and esophageal cancers, demonstrating that 3D pathology may have broader potential across various cancer types.

The full findings will be shared at the Global Breast Cancer Conference in South Korea on April 17. https://gbcc.kr/Main.asp

Implications for breast cancer treatment and drug guidelines

T-DXd has demonstrated significant efficacy in tumors with HER2 expression. However, tumors classified as HER2-null under conventional pathological testing are ineligible for T-DXd treatment. By detecting HER2 more precisely using 3D pathology methods, we can identify more patients eligible for T-DXd therapy.

In addition to cancer patients, JelloX’s 3D pathology technology has the potential to expand possibilities across healthcare stakeholders:

For physicians: This advanced diagnostic tool offers a more comprehensive patient data set and, when integrated with AI, helps reduce physician workloads.For pharmaceutical companies and research institutions: The technology enhances companion diagnostics (CDx) for drug usage and is a valuable tool for new drug development.For healthcare systems: 3D pathology optimizes medical resource allocation and minimizes unnecessary financial and healthcare burdens.

About JelloX Biotech Inc.

Based in Hsinchu, Taiwan, JelloX Biotech Inc. is a startup that focuses on advancing cancer pathology through 3D digital imaging and AI technology. 

For more information, please visit: https://jellox.com/en/home/

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/greater-precision-of-her2-expressing-breast-cancer-treatment-with-3d-pathology-new-jellox-research-collaboration-302431092.html

SOURCE JelloX Biotech Inc.

Continue Reading

Technology

HTX Completes Fireblocks Off-Exchange Integration, Advancing Institutional Trading Security and Efficiency

Published

on

By

SINGAPORE, April 16, 2025 /PRNewswire/ — HTX, a leading global cryptocurrency exchange, has successfully integrated and launched Fireblocks Off-Exchange, a next-generation solution for institutional trading.

“This integration represents a strategic expansion of HTX’s institutional offerings,” said Justin Sun, Advisor to HTX. “Fireblocks’ state-of-the-art technology enhances our platform’s security infrastructure while streamlining institutional operations within a compliant framework. Looking ahead, we remain committed to delivering cutting-edge solutions that make HTX the preferred gateway for institutions entering the digital asset market.”

This milestone reinforces HTX’s commitment to delivering a secure, compliant, and seamless trading environment for its global institutional clientele.

Fireblocks Off-Exchange: Revolutionizing Institutional Asset Security

Fireblocks Off-Exchange enables institutions to securely trade digital assets by maintaining funds in self-custodied, off-exchange collateral accounts, while simultaneously receiving 1:1 credit on the exchange. This dramatically reduces counterparty risk while maintaining the speed and capital efficiency of centralized trading.

The solution facilitates rapid, low-cost settlement across platforms, ensuring assets remain under institutional-grade security throughout the trade lifecycle. A robust disaster recovery mechanism guarantees recoverability of funds even under extreme conditions, enabling institutional clients to retain control over private keys while accessing deep exchange liquidity.

HTX: Reinforcing Institutional Confidence in the Crypto Market

By deploying Fireblocks Off-Exchange, HTX strengthens its platform’s regulatory posture and operational resilience—critical factors in today’s evolving digital asset landscape. The integration aligns with HTX’s broader mission to advance institutional participation through enhanced asset protection and compliance infrastructure.

Since the launch, HTX has onboarded numerous institutional clients and recorded a 200% increase in trading volume, validating market demand for secure off-exchange settlement models.

A Step Toward the Future of Compliant Institutional Trading

As the crypto industry continues to mature, HTX remains committed to innovation in asset protection, regulatory alignment, and institutional services. The Fireblocks Off-Exchange integration marks another key milestone in HTX’s journey to provide a best-in-class, compliant trading experience tailored to institutional needs—positioning the exchange as a global leader in secure digital asset trading.

About HTX

Founded in 2013, HTX has evolved from a virtual asset exchange into a comprehensive ecosystem of blockchain businesses that span digital asset trading, financial derivatives, research, investments, incubation, and other businesses.

As a world-leading gateway to Web3, HTX harbors global capabilities that enable it to provide users with safe and reliable services. Adhering to the growth strategy of “Global Expansion, Thriving Ecosystem, Wealth Effect, Security & Compliance,” HTX is dedicated to providing quality services and values to virtual asset enthusiasts worldwide.

To learn more about HTX, please visit HTX Square or https://www.htx.com/, and follow HTX on X, Telegram, and Discord.

Photo – https://mma.prnewswire.com/media/2666638/1.jpg
Logo – https://mma.prnewswire.com/media/2391903/image_ID__Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/htx-completes-fireblocks-off-exchange-integration-advancing-institutional-trading-security-and-efficiency-302430596.html

Continue Reading

Technology

Rio Tinto and AMG Metals & Materials to assess low-carbon aluminium project in India

Published

on

By

LONDON, April 17, 2025 /PRNewswire/ — Rio Tinto and AMG Metals & Materials (AMG M&M), an energy transition solutions provider, have signed a Memorandum of Understanding (MOU) to jointly assess the feasibility of developing an integrated low-carbon aluminium project powered by renewable energy in India. AMG M&M is promoted by the two founders of Greenko and AM Green.

Together, the parties will consider the potential development of up to a 1 million tonnes per annum (Mtpa) primary aluminium smelter and 2 Mtpa of alumina production, both powered by renewable wind and solar energy firmed by pumped hydro storage. The development will comprise a study to evaluate a potential first phase 500,000 tonnes per annum primary aluminium smelter in a favourable location in India.

Rio Tinto Aluminium Chief Executive Jérôme Pécresse said: “This study is an important step in our ambition to grow our global, low-carbon aluminium footprint while exploring new project delivery approaches and opportunities in emerging markets. Partnering with AMG Metals & Materials enables us to assess how we can develop low-cost responsible aluminium production powered by renewable energy. With its rapid economic growth and strategic position, India is a compelling location for this potential project and aligns with our long-term vision for a globally more diverse and resilient aluminium business.”

As part of the study, AMG M&M will examine a firmed renewable energy solution with Greenko, while Rio Tinto will explore a commercial alumina solution. The study will also assess smelting technology options to determine the most cost-effective solution for the project.

Group President of AMG Metals & Materials and Greenko Mahesh Kolli said: “Over the last few years, we have been able to deliver a multitude of decarbonization solutions comprising electricity, molecules, chemicals and fuels. We are excited to expand that further to the materials space. This MOU could deliver much needed low-carbon metal at scale to propel decarbonization initiatives in global supply chains across auto, construction, consumer packaging and many more segments.”

About AMG Metals & Materials

AMG Metals & Materials is incorporated by Anil Chalamalasetty and Mahesh Kolli, the founders of Greenko Group, one of India’s leading energy transition solutions providers, and AM Green, a global decarbonization solution provider. Greenko has a near-term operational renewable energy capacity of 10 GW across solar, wind and hydro and is building 100 GWh of single cycle storage capacity across India. AM Green is developing low-carbon ammonia projects across multiple locations in India with a goal to reach 5 Mtpa of green ammonia capacity by 2030. Its first plant currently under construction in Kakinada with a projected capacity of 1 Mtpa of green ammonia will be one of the world’s largest RFNBO compliant green ammonia facilities, supporting efforts to achieve net zero targets both in India and OECD markets. AM Green is also developing production capabilities for other net zero molecules and chemicals including green caustic soda, e-methanol, olefins & biofuels for decarbonization in hard to abate industries. Further information at www.amgreen.com

Contacts

AMG Metals & Materials

Suheil Imtiaz
Public Affairs & Strategic Communication
suheil.m@amgreen.com

Rio Tinto
media.enquiries@riotinto.com

 

Media Relations,

Media Relations,

Media Relations,

United Kingdom

Australia

Canada

Matthew Klar

Matt Chambers

Simon Letendre

M +44 7796 630 637

M +61 433 525 739

M +1 514 796 4973

David Outhwaite

Michelle Lee

Malika Cherry

M +44 7787 597 493

M +61 458 609 322

M +1 418 592 7293

Rachel Pupazzoni

Vanessa Damha

M +61 438 875 469

M +1 514 715 2152

Media Relations,

US

Jesse Riseborough

M +1 202 394 9480

Investor Relations,

Investor Relations,

United Kingdom

Australia

Rachel Arellano

Tom Gallop

M: +44 7584 609 644

M +61 439 353 948

David Ovington

Amar Jambaa

M +44 7920 010 978

M +61 472 865 948

Laura Brooks

M +44 7826 942 797

Weiwei Hu

M +44 7825 907 230

Rio Tinto plc

Rio Tinto Limited

6 St James’s Square

Level 43, 120 Collins Street

London SW1Y 4AD

Melbourne 3000

United Kingdom

Australia

T +44 20 7781 2000

T +61 3 9283 3333

Registered in England

Registered in Australia

No. 719885

ABN 96 004 458 404

riotinto.com
Category: General

Logo – https://mma.prnewswire.com/media/2490224/5271756/AM_GREEN_Logo.jpg
Logo – https://mma.prnewswire.com/media/2666530/Rio_Tinto.jpg

View original content:https://www.prnewswire.co.uk/news-releases/rio-tinto-and-amg-metals–materials-to-assess-low-carbon-aluminium-project-in-india-302430747.html

Continue Reading

Trending